Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

TherapeuticsMD Inc. buy tamam

Start price
€320.35
18.03.17 / 50%
Target price
€600.00
27.09.17
Performance (%)
-30.72%
End price
€221.95
27.09.17
Summary
This prediction ended on 27.09.17 with a price of €221.95. Massive losses of -30.72% were the result for the BUY prediction by tamam. tamam has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
TherapeuticsMD Inc. -7.692% -7.692% -62.304% -96.852%
iShares Core DAX® 1.395% -0.696% 15.472% 15.907%
iShares Nasdaq 100 2.287% 7.501% 34.748% 53.474%
iShares Nikkei 225® 1.617% 2.769% 11.442% 8.194%
iShares S&P 500 0.659% 4.280% 26.778% 45.322%

Comments by tamam for this prediction

In the thread Therapeuticsmd Inc. diskutieren
Prediction Buy
Perf. (%) -30.72%
Target price 12.000
Change
Ends at 27.09.17

TherapeuticsMD, Inc., an innovative women’s healthcare company!



On Mon December 5, 2016 TherapeuticsMD announced positive top-line results from its pivotal
 phase 3 Replenish Trial of TX-001HR.





Der Produktkandidat TX-001HR ist eine neuartige Kombination von Estradiol und Progesteron (
identisch in der chemischen Struktur) zur Behandlung von vasomotorischen Symptomen (VMS) im Zusammenhang mit der Menopause, um vor allem tägliche Hitzewallungen und Nachtschweiß oft in der Menopause zu reduzieren.
Es wird geschätzt, dass mehr als 90% der Frauen VMS erleben. Die meisten bewerten die Schwere der Hitzewallungen als mäßig bis schwer.


Upcoming catalysts timeline

1) November 3, 2017: An official meeting with the FDA will be held to
discuss whether the company should resubmit the NDA for TX-004HR and
what changes should be made in the new NDA.

2) Early December 2017: If the FDA allows for a resubmission, an announcement
within a month of resubmission will be made with regard to
classification.

3) Early January 2018: If the FDA classifies the resubmission as Class 1, the FDA will announce the final
approval decision for TX-004HR.

4) Early May 2018: If the FDA classifies the resubmission as Class 2, the FDA will announce
 the final approval decision for TX-004HR.

5) Q3 2018: The FDA comes back with an announcement with regard to an approval decision for TX-001HR.











Prediction Buy
Perf. (%) -30.72%
Target price 12.000
Change
Ends at 27.09.17

(Vom Mitglied beendet)

Stopped prediction by tamam for TherapeuticsMD Inc.

buy
TherapeuticsMD Inc.

Start price
Target price
Perf. (%)
€207.01
06.12.18
€200.00
04.11.21
-84.30%
05.11.21